LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 ( AnxA2 ) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2 . LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles.
Products | Products > Peptides | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Annexin A
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.